Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.

Also called NCT06739044

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 494 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06739044
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06739044. Randomized; no masking; primary purpose treatment. Start 2023-09-20 (actual); primary completion 2024-10-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
Intervention (Drug)
Ozempic®
Intervention (Drug)
HDG1901
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06739044
Content hash
192cd08dd937536df0c60de0b9e1c870f3c7083925a3dc046e6a441bfdc6bbda